After adjusting for age, sex, hypertension, hyperlipidemia, CVD, CAD, CKD, and use of GLP-1 agonists, insulin, metformin, diuretics, statins, aspirin, ACEIs/ARBs, NSAIDs, and PPIs, the SGLT2i group had an adjusted HR of 0.66 (95% CI, 0.57-0.75; P < .001) for AKI and 0.56 (95% CI, 0.37-0.84; P = .005) for AKI-D compared with the DPP4i group (Table 2). The gene discussed is INS; the disease is hyperlipidemia.